Press releases

Baxter International Third Quarter 2014 Financial Results Conference Call

Vaccines Franchise to be Reported as Discontinued Operation

DEERFIELD, Ill., October 9, 2014 - Baxter International Inc. (NYSE:BAX) will host a quarterly conference call to discuss its third quarter 2014 financial results on Thursday, October 16, 2014, at 7:30 a.m. Central Time.

Beginning in the third quarter 2014, Baxter will be reclassifying and reporting the operating results from its Vaccines Franchise as a discontinued operation for all periods presented. As disclosed in July, Baxter entered into an agreement to sell its commercial vaccines business, including NeisVac-C, a vaccine which helps protect against meningitis caused by group C meningococcal meningitis, and FSME-IMMUN, which helps protect against tick-borne encephalitis (TBE), an infection of the brain transmitted by the bite of ticks infected with the TBE-virus. The divestiture is expected to be completed in the fourth quarter of 2014. Concurrent with the sale, the company also committed to a plan to divest R&D programs focused on the development of influenza and Lyme disease vaccines. Historical financial results for the Vaccines Franchise are available on Baxter's website at

To access the conference call, please dial 866-837-9782 (domestic) or 703-639-1420 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you. This call is being webcast by Nasdaq OMX and can be accessed at Baxter's website at The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission.

Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.  As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

This release includes forward-looking statements concerning the divestiture of Baxter's vaccines business, including with respect to the closing of the sale of the commercial vaccines business and the financial impact of the contemplated divestiture on the company. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: failure to obtain the necessary approvals and consents or to satisfy other closing conditions; a material adverse change in the commercial vaccines business; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; product quality or patient safety concerns; and other risks identified in Baxter's most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements. Financial schedules are available on Baxter's website.